ArticleBreast cancer (Tokyo, Japan)2025
Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer.
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer remain at risk of recurrence even beyond 5 years post-surgery. The monarchE and the POTENT trials have demonstrated the efficacy of adding abemaciclib and S-1, respectively, to adjuvant endocrine therapy for patients with intermediate to high-risk luminal breast cancer. Given the broad eligibility criteria of the POTENT trial, this study aimed to determine the optimal selection criteria for adjuvant S-1 therapy in HR-positive/HER2-negative early breast cancer.
methodsWe analyzed the prognosis of POTENT-eligible patients with HR-positive/HER2-negative early breast cancer who underwent surgery at our institute from 1981 to 2023. Kaplan-Meier curves were established, and differences were assessed using the log-rank test.
resultsThe analysis included 2099 patients. Among lymph node-negative patients eligible for the POTENT trial, those with grade 2 tumors < 3 cm demonstrated significantly better disease-free survival (DFS) than those with tumors ≥ 3 cm, while patients with grade 3 tumors < 2 cm demonstrated significantly improved DFS compared with those with tumors ≥ 2 cm. Lymph node-negative patients with "grade 2 & ≥ 2 cm, < 3 cm" and "grade 3 & < 2 cm" disease had significantly better DFS compared with the "remaining POTENT eligible" patients (p = 0.009).
conclusionsThe results of this study showed that the prognosis for lymph node-negative early breast cancer patients classified as "grade 2 & ≥ 2 cm, < 3 cm" and "grade 3 & < 2 cm" was favorable. The benefit of adding S-1 to endocrine therapy to these groups may be marginal.
Indexed as
Identifiers
40413312What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.